February 2, 2026 - ChartAlert®

COFORGE – Q3 FY26 Earnings Call – 23-Jan-26

COFORGE targets 25%+ FY27 growth via diversification and cross-sell, with EBIT margin expansion to 15.5%+ hinging on AI scalability and cost discipline. Outcome-based pricing supports upside, but FX, subcontractor costs, and M&A integration risks temper margin gains.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key variables: Encora closes by Q1 FY27; Sabre cross-sell delivers $50M incremental revenue; Healthcare/Hi-Tech grow 50%+ YoY; hedge losses normalize.
Outcome: Revenue grows 25% YoY (FY27); EBIT margin expands to 15.5% on AI-driven productivity and Cigniti accretion. FCF/PAT sustains at 100%+. Implication: EPS outperforms; margin expansion justifies premium valuation.

KEC – Q3 FY26 Earnings Call – 30-Jan-26

KEC’s topline resilience (T&D/SAE-driven) contrasts with margin/cash flow pressures (legacy projects, labor, water). FY28 9–10% EBITDA hinge on execution cleanup; near-term guidance downgrades reflect structural delays, not cyclical weakness. Order book quality high, but conversion risks persist.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Water project collections normalize (INR 800 crore FY26 revenue), metro closures accelerate in H2 FY26, and INR 30,000 crore order intake in FY27 (12% success rate).
Outcome: Revenue growth 12–14%, EBITDA margins 7.5–8%, and net debt at INR 5,500 crore. T&D drives 60% of growth; SAE/Cables offset Civil weakness.

KEI – Q3 FY26 Earnings Call – 22-Jan-26

KEI’s topline hinges on Sanand execution (INR6,000 crore swing) and export scalability (20% mix), while margins depend on copper pass-through (10–15% pricing power) and EHV mix (25% share)—11% EBITDA achievable if risks are managed, but downside skews to execution delays and commodity cycles.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Sanand on track + copper stable (LME $9,000) + export 20%.

Topline: INR11,000 crore (18% growth) with Sanand contributing INR2,700 crore.
EBITDA Margin: 11.2% (export mix + EHV ramp).
Implication: 20% CAGR validated; ROCE 15%+ by FY29.

OBEROIRLTY – Q3 FY26 Earnings Call – 20-Jan-26

OBEROIRLTY’s FY26 topline growth hinges on launch execution (50% probability of partial slippage), while FY27’s “big year” thesis requires flawless RERA/commencement timelines; margins are structurally supported by premium pricing but vulnerable to absorption risks in Goregaon/Borivali, and FCF inflection is deferred to FY27 pending land monetization.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 50% of Q4 FY26 launches execute (Goregaon, Borivali, but NCR slips); (2) Premium demand holds (Rs. 50,000+/sq. ft. sales at 70% of inventory); (3) Sky City leasing hits 80% by FY26-end.
Outcome: Revenue growth 15–20% YoY in FY27 (spillover effect), margins stable (±50 bps) on pricing power; FCF breakeven by H2 FY27 as land spends monetize. Thane’s mixed-use projects gain traction, adding Rs. 1,500 crore to pipeline.

ADANIGREEN – Q3 FY26 Earnings Call – 23-Jan-26

ADANIGREEN’s topline growth hinges on grid evacuation timing and merchant price recovery, while bottomline resilience depends on storage arbitrage execution and commodity cost containment; margins remain structurally high (90%+) but face cyclical pressure from wind volatility and merchant pricing.

1–2 minutes

3-Scenario Framework

📊 Base Case (60% Probability)

Grid augmentation completes by March 2026 (2–3 GW), and wind speeds normalize in H1 FY27. Merchant realizations recover to ₹2.50–3.00/unit (solar) on peak demand. Battery storage (3.5 GWh) operationalizes as planned, enabling 10–15% revenue uplift from arbitrage. EBITDA margin sustains at 90%+, with ₹16,000 crore power supply EBITDA achieved by FY26 end. Debt/EBITDA improves to 5x by FY27.

DRREDDY – Q3 FY26 Earnings Call – 21-Jan-26

Dr.Reddy’s topline growth hinges on Semaglutide/Abatacept execution and EM resilience, while margins face structural pressure from Lenalidomide exit, FX, and biosimilar delays; base case implies 6–8% revenue growth with 24–26% EBITDA, but bear-case risks skew asymmetric.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Semaglutide launches in Canada (May 2026, $50/unit) and India (March 2026, $30/unit), contributing $150–200M revenue. Abatacept EU approval (July 2027) and US Rituximab re-inspection (H1CY27) proceed as guided. EM grows 20% YoY; India sustains 15%+ organic growth. EBITDA margins recover to 24–26% on cost controls. Implication: 6–8% revenue growth; 10–12% EPS growth.

AXISBANK – Q3 FY26 Earnings Call – 26-Jan-26

Axis Bank’s base case sees NIM stabilizing near 3.6–3.7% with ROE at 14–15%, while bear case risks compression to 3.4–3.5% and ROE 12–13%. Bull case offers upside with NIM above 3.8% and ROE 16%+, hinging on deposit growth and digital monetization.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Triggers: Deposit growth converges in 15–18 months, retail disbursements sustain +20% YoY, no further rate cuts.
Outcome: NIM stabilizes at 3.6–3.7% (Q4 dip offset by 2027 rebalancing), credit costs 60–70 bps, ROE 14–15%. CET-1 remains >14% (AT1 issuance likely). Action: Model 58–60% retail mix by FY28, watch Neo platform monetization.